Gilead Sciences ((GILD)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Gilead Sciences, in collaboration with Arcus Biosciences, recently updated their clinical study titled A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB308 in Combination With AB122 in Participants With Advanced Malignancies. The study aims to assess the safety, tolerability, and clinical activity of AB308 combined with zimberelimab (AB122) in patients with various advanced cancers, including non-small cell lung cancer and melanoma. This research is significant as it explores new treatment options for challenging malignancies.
The intervention involves two drugs: AB308 and zimberelimab, both administered intravenously. AB308 is being tested in combination with zimberelimab to enhance its therapeutic effects against advanced malignancies.
This interventional study is designed as a non-randomized, open-label, sequential trial with the primary purpose of treatment. It focuses on dose escalation and expansion to evaluate the optimal dosing strategy.
The study began on February 22, 2021, and was completed as of August 27, 2025. The primary completion date marks when the main data collection for the primary outcome measure was finalized, while the last update date indicates the most recent information provided.
The completion of this study could influence Gilead’s stock performance positively, as successful results might enhance investor confidence and market position in oncology. Competitors in the oncology space may need to respond to any breakthrough findings from this study.
The study is completed, with further details available on the ClinicalTrials portal.